Fosun Pharma's new crown vaccine has been urgently used in Hong Kong

January 26, 2021 / Medical Information List: Fosun Pharma's new crown vaccine has been used urgently in Hong Kong; Shanghai Xinyi Veotic Pharmaceuticals' allopurinol tablets passed the consistent evaluation; Mercadon stops developing COVID-19 candidate vaccine... Daily fresh medicine news, speed reading society and you pay attention to! Part1 Policy Brief Beijing 2 new local confirmed cases are Daxing reported january 25 from 0:00 to 24:00, 2 new locally confirmed cases, no new suspected cases and asymptomatic infections;
two confirmed cases were all in the Tiangongyuan Street Fusion Community in Daxing District.
has carried out epidemiological investigations into the above-mentioned confirmed cases and implemented control measures as required.
(Beijing Daily) Heilongjiang added 53 new confirmed cases of 24 new asymptomatic January 25 0-24, Heilongjiang Province added 53 new confirmed cases of neo-crown pneumonia, of which asymptomatic infected people into confirmed cases 25 cases.
1 case was cured and discharged from the hospital (Wangkui County, Yuhua City).
24 new cases of asymptomatic infection were reported (7 cases in Wangkui County, Hulan District, Harbin City, 6 cases in Limin Development Zone, and 2 cases in Dauri District, Harbin City).
(CCTV News) Beijing Daxing sampled 11,221 environmental specimens 76 positive January 26, Beijing's 221st new crown pneumonia epidemic prevention and control press conference was held.
- Beijing headline reporters at the meeting was informed that Daxing District People's Government Deputy District Director Han Xinxing introduced the region's epidemic management situation.
Daxing District continued to carry out environmental testing and killing work, a total of 11,221 environmental specimens sampled, of which 76 positive, mainly in the case of home-based, the rest for private cars, elevator buttons, garbage cans and other points.
(Tencent News) 3 pharmaceutical enterprise inspection does not meet GMP January 25, Jiangxi Provincial Drug Administration issued the 2021 No. 1 drug production supervision and inspection results announcement, three pharmaceutical companies Jiangxi Jinding Pharmaceutical Co., Ltd., Jiangxi Yan Pharmaceutical New Pharmaceutical Co., Ltd., Jiangxi Province, Shanghai Gao County Oxygen Co., Ltd. inspection conclusions do not meet GMP requirements.
(Jiangxi Provincial Drug Administration) Part2 after observation of the Shanghai Stock Exchange to terminate the Dana Biotech Board IPO on January 25, the Shanghai Stock Exchange issued "on the termination of Dana (Tianjin) Biotech Co., Ltd. initial public offering of shares and the listing of the Board review decision."
the decision to withdraw the application documents in view of the application submitted recently by the sponsor, CITIC Securities.
in accordance with the relevant provisions of Article 67 of the Rules for the Review of the Listing of Shares of the Shanghai Stock Exchange, the SSE has decided to terminate the examination of the initial public offering of shares of Dana Bio and the listing of the shares on the Stock Exchange.
(Pharmaceutical Rubik's Cube) Qiming Ventures completed the sixth phase of rmb fund 2,852 million yuan to raise capital Qiming Ventures sixth phase of RMB fund raising day officially closed, the size of the fund reached 2,852 million yuan.
the fund raising, Qiming Ventures has a total of $5.9 billion under management, and RMB funds and U.S. dollar funds will continue to make efforts in TMT and Healthcare.
(American News Agency) Boan Bio received several more investment cumulative financing amount of 880 million yuan Green leaf pharmaceutical group announced that its Boan Bio received 195 million yuan from CCB International, Shidao Company and other investment institutions.
, Boan Bio has received a total of about 880 million yuan in financing from several investment institutions in about 1 month.
news that Amjin China began laying off workers last month, according to news.
china is laying off staff who failed to enter the country's health-care talks for the first time, according to a new government source.
(Sina Pharmaceutical News) Part3 drug news Roche long-acting dual-specific antibody Phase 3 clinical results positive January 25, Roche announced that its dual-specific antibody faricimab in the treatment of neovascular age-related macular degeneration patients in two global Phase 3 clinical trials TENAYA and LUCERNE obtained positive top-line results.
faricimab is the first double-specific antibody designed for the eye.
it targets two different paths, Ang-2 and VEGF-A, which affect vision by disrupting the stability of blood vessels by causing new leakage blood vessels to form and increasing inflammation.
by blocking both path paths, faricimab is designed to stabilize blood vessels and may lead to better long-term vision outcomes for people with retinal disease.
(Pharmaceutical Mingkangde) Tiantian Bio and MorphoSys announced that TJ2101 clinical studies completed the first patient dosing January 26, Tiantian Biology and German MorphoSys jointly announced that TJ210/MOR210 single-drug treatment recurrence or resusable advanced solid tumors of the United States Phase 1 dose climbing trial has completed the first patient.
phase 1 clinical study was designed to assess the safety, toerability, pharmacodynamics and pharmacodynamics of TJ210/MOR210.
(A.M.) Mercadon stopped developing COVID-19 candidate vaccines on January 25, Mercadon announced that it will stop developing COVID-19 candidate vaccines V590 and V591, and plans to focus its COVID-19 research strategy and production capacity on advancing MK-4482 and MK-7110 two therapeutic candidates.
decision comes after Mercedon reviewed the results of its Vaccine Phase 1 clinical study.
in the study, both V590 and V591 showed good tolerance, but their immune responses were lower than those of immune responses to natural infections and to other SARS-CoV-2/COVID-19 vaccines.
(Sina Pharmaceutical News) AbbVie JAK inhibitors have been approved for the treatment of psoriasis arthritis and strong spina blinitis Today, AbbVie announced that the European Commission has approved its JAK inhibitor Rinvoq extended adaptation for the treatment of adult active psoriasis arthritis patients.
Rinvoq can be used as a monotherapy or in combination with methotrexate.
Rinvoq has also been approved for the treatment of adult active orthopathic spina blinitis patients with poor conventional therapy.
this is the first time this JAK inhibitor has been approved to treat both groups of patients.
(Pharmaceutical Mingkangde) Pfizer/Merck Bavencio first-line maintenance treatment of metastatic urethra skin cancer was approved by the European Union on January 25, Pfizer and Merck jointly announced that the European Commission has approved anti-PD-L1 therapy Bavencio, for first-line maintenance treatment after receiving platinum-containing chemotherapy, the disease did not progress in the local advanced or metastatic urethroid skin cancer (UC) adult patients.
is the 10th most common cancer in the world, and UC is the most common type of bladder cancer, accounting for about 90 percent of all cases.
metastasis UC is difficult to treat, with a five-year survival rate of only 5%.
(Sina Pharmaceutical News) Wantay Bio: the company's new coronavirus-related testing products to obtain EU CE certification January 26, Vantai Biological Announcement, the company's new coronavirus (2019-nCoV) antigen testing kit (enzyme-linked immunity method), the new coronavirus (2019-nCoV) antigen testing kit (enzyme-linked immunity method), the new coronavirus (2019-nCoV) IgG anti-medical test kit (enzymatic immune method) and new coronavirus (2019-nCov) IgG antibody rapid detection kit (collosome gold method) three products, recently obtained the EUROPEAN CE certification.
(Vantai Bio) EUSA Pharma/ Baiji Shenzhou announced that SYLVANT's listing application in China has been accepted EUSA Pharma and Baiji Shenzhou jointly announced on the 25th that NMPA has accepted Savien®'s listing license application and included in the priority review.
Injection Stoxima is a monoclonal antibody that has been approved by the EMA and FDA for the treatment of adult idiopathic multi-center Castelman disease patients with HUMAN immunodeficiency virus-negative and human herpes virus 8-negative.
(AGENCY) the world's first declared clinical BTK-PROTAC came on January 26, Hesco Pharmaceuticals disclosed that its wholly-owned subsidiary Sichuan Haisco Pharmaceuticals recently received a "notice of acceptance" issued by NMPA, its declared HSK29116 bulk agent drug clinical trial application was accepted by NMPA.
HSK29116 is an oral PROTAC small molecule anti-tumor drug that selectively blocks BTK kinase activity and interferes with B cell development by regulating signaling path paths to control the progression of various B-cell malignancies.
(Pharmaceutical Rubik's Cube) China Resources Double Crane: Medium/ Long Chain Fat Breast Injection (C8-24) obtained the drug registration certificate January 26, China Resources Double Crane Announcement, Medium/Long Chain Fat Milk Injection (C8-24) obtained the NMPA approved drug registration certificate.
the drug as an extraintestinal nutrition drug, energy supplement, used for gastrointestinal nutrition, to meet the requirements of energy and essential fatty acids.
(China Resources Double Crane Announcement) Xinbico ®Dubao® was approved for the treatment of mild asthma in adults and adolescents over 12 years of age January 26, AstraZenech ®Dubao® has been officially approved by the NMPA for anti-inflammatory relief treatment for adults and adolescents over 12 years of age with mild asthma.
is the first combination therapy approved in China to treat mild asthma and will provide a full-scale management program for people with mild, moderate and severe asthma.
Tiansli: Subsidiary company metformin tablets through generic drug consistency evaluation January 26, Tiansli announced that recently, the company's wholly-owned subsidiary Jiangsu Diyi received NMPA issued on the specifications of metformin tablets 0.25g "drug supplementary application approval notice", the drug through generic drug consistency evaluation.
metformin tablets preferred for simple diet and physical exercise to control blood sugar ineffective type 2 diabetes, as a national essential drug, and entered the National Health Insurance Directory (Class A).
(Tiansli announcement) Shanghai Xinyi Veolin tablets through the consistency evaluation recently, NMPA official website shows that Shanghai Xinyi Wanyi Pharmaceuticals allopurinol tablets through the consistent evaluation, for the first time in the country.
is a commonly used drug for the treatment of high uric acidemia and gout caused by excessive uric acid, and is a class A variety of national health insurance.
(Minenet) Kanghong Pharmaceuticals Compaxip eye injection registration application was accepted by CDE january 25, according to the CDE official website, Kanghong Pharmaceuticals "Compaxip eye injection" 2.2 new drug registration application was accepted by CDE, this will be Compaxipu eye injection in china submitted the fourth listing application, it is understood that the declared adaptation is the retinal venous obstruction caused by macular edema.
(CPhl Pharmaceuticals Online) launched an updated version of the new crown vaccine for the new coronal mutant virus Moderna today, Moderna announced that the new crown vaccine mRNA-1273 developed by the company has shown the meso-emerging activity of the new coronary mutant strain in in-body trials.
serums of individuals vaccinated against the new crown have a median effect on a variety of key mutants, including the B.1.1.7 and B.1.351 strains originally found in the United Kingdom and South Africa.
Moderna said it had initiated preclinical and Phase 1 clinical studies to test an mRNA vaccine for the new coronary mutant strain to enhance the vaccine's effectiveness in order to prevent the effects of the new coronavirus on the vaccine's long-term protection in advance.
(Pharmaceutical Mingkangde) Fosun Pharma New Crown Vaccine was approved for emergency use in Hong Kong on January 25, Fosun Pharma and BioNTech jointly announced that COMIRNATY® a new crown vaccine based on BioNTech's mRNA technology has been approved for emergency use in Hong Kong by the Food and Health Bureau of the Hong Kong Special Administrative Region.
future supply of vaccines to Hong Kong will be produced directly from BioNTech's plant in Germany for supply, distribution and application under the HKSAR Government's new crown vaccination programme.
(Fosun Pharma)